China’s NMPA approves Bayer’s Nubeqa for additional prostate cancer indication

The Chinese National Medical Products Administration or NMPA, has approved the oral androgen receptor inhibitor Nubeqa or darolutamide, in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer or mHSPC. Nubeqa is already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer or nmCRPC, who are at high risk of developing metastatic disease. "Prostate cancer cases in China have increased significantly in recent years. Compounding that, nearly a third of patients who are newly diagnosed will have metastatic disease. We are therefore delighted that patients in China will now have a new treatment option for metastatic hormone-sensitive prostate cancer that delays disease progression, extends survival and maintains quality of life", said Christine Roth, Member of the Executive Committee of Bayer’s Pharmaceuticals Division and Head of the Oncology SBU at Bayer. "Bayer is committed to improving health outcomes for people living with prostate cancerand that as many eligible patients as possible gain access to Nubeqa." Reference Link